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We conducted a prospective multicenter study in Spain to characterize the mechanisms38
of resistance to amoxicillin/clavulanate (AMC) in Escherichia coli. Up to 44 AMC-39
resistant E. coli isolates (CMI ≥32/16 µg/mL) were collected at each of the seven 40
participant hospitals. Resistance mechanisms were characterized by PCR and41
sequencing. Molecular epidemiology was studied by pulsed field gel electrophoresis42
(PFGE) and by multilocus sequence typing. Overall AMC resistance was 9.3%.43
The resistance mechanisms detected in the 257 AMC-resistant isolates were: OXA-144
production (26.1%), hyperproduction of penicinillinase (22.6%), production of45
plasmidic AmpC (19.5%), hyperproduction of chromosomic AmpC (18.3%), and46
production of inhibitor-resistant TEM (IRT) (17.5%). The IRTs identified were TEM-47
40 (33.3%), TEM-30 (28.9%), TEM-33 (11.1%), TEM-32 (4.4%), TEM-34 (4.4%),48
TEM-35 (2.2%), TEM-54 (2.2%), TEM-76 (2.2%), TEM-79 (2.2%), and the new TEM-49
185 (8.8%). By PFGE, a high degree of genetic diversity was observed although two50
well-defined clusters were detected in the OXA-1-producing isolates: the C1 cluster51
consisting of 19 phylogroup A/ST88 isolates, and the C2 cluster, 19 phylogroup52
B2/ST131 isolates (16 of them producing CTX-M-15); each of the clusters was detected53
in six different hospitals. In total, 21.8% of the isolates were serotype O25b/phylogroup54
B2. AMC resistance in E. coli is widespread in Spain at the hospital and community55
levels. A high prevalence of OXA-1 was found. Although resistant isolates were56
genetically diverse, clonality was linked to OXA-1-producing isolates of the STs 88 and57
131. Dissemination of IRTs was frequent, and the epidemic O25b/B2/ST131 clone58




Escherichia coli is an important etiologic agent for both nosocomial- and62
community-acquired infections in humans (10, 14, 23). Amoxicillin-clavulanate (AMC)63
is one of the most widely used antibiotics in many countries (3, 12, 16). In Spain, a64
34.7% increase in community use of AMC was recorded from 2000 to 2006 (21).65
Recently, blood isolates of E. coli non-susceptible to AMC increased from 9.3% (2003)66
to 25.9% (2010) in Spain, according to the European Antimicrobial Resistance67
Surveillance Network (EARS-Net) (9, 21).68
Enzymatic mechanisms of E. coli resistance to AMC include: hyperproduction69
of plasmid-mediated class A β-lactamases such as TEM-1 and SHV-1 (19,32), plasmid-70
mediated AmpC-type β-lactamase (p-AmpC) (22), chromosomal AmpC β-lactamase (c-71
AmpC) (22), production of inhibitor-resistant TEM (IRT) β-lactamases (18,28), 72
plasmid-mediated β-lactamase OXA-1 (33), and complex mutant TEM (CMT) enzymes 73
than combine IRT- and extended-spectrum β-lactamase (ESBL)-type substitutions (27).    74
In spite of the significant increase in AMC use in the last years, there is little75
recent information available about the prevalence of AMC resistance mechanisms in E.76
coli; most previous studies analyzed strains isolated more than 10 years ago from single77
hospitals in the United States (13, 29), France (17), and Spain (20, 25).78
Accordingly, the aims of this prospective Spanish national multicenter study79
were to investigate the epidemiology and mechanisms of AMC resistance in clinical80
isolates of E. coli causing both community- and nosocomial infections.81
82
Material and methods83
Study design and bacterial isolates84
5
A prospective multicenter study was designed to obtain E. coli isolates resistant85
to AMC (MIC ≥32/16 µg/mL and/or disk inhibition zone ≤13 mm according to Clinical 86
and Laboratory Standards Institute [CLSI] [8]) from clinical samples collected between87
January 2010 and May 2010. Seven university hospitals of six Spanish Autonomous88
Communities and members of the Spanish Network for the Research in Infectious89
Diseases (REIPI) participated. Investigators at these hospitals were asked to collect up90
to 22 consecutive community- and 22 nosocomial-acquired, non-duplicated isolates of91
E. coli resistant to AMC.92
Nosocomial-acquired isolates were defined as those acquired at least 48 hours93
after hospital admission. Putatively community-acquired isolates were those isolated in94
the community or within 48 hours of hospital admission.95
96
Susceptibility testing97
The disk diffusion and/or microdilution susceptibility tests were performed using98
different automated systems in each participating laboratory. All isolates were99
submitted to the antibiotic laboratory of the Centro Nacional de Microbiología100
(Majadahonda, Madrid), where additional confirmatory antibiotic susceptibility testing101
was performed with the agar dilution method according to the CLSI guidelines (7).102
Control strains used were E. coli ATCC 25922 and E. coli ATCC 35218. The103
production of extended spectrum β-lactamases (ESBLs) was studied by the double-disc 104
synergy test and/or Etest ESBL using cefotaxime and ceftazidime as substrates (AB105
Biodisk, Solna, Sweden).106
107
Molecular characterization of mechanisms of resistance to AMC108
6
The blaTEM gene and its promoter region were assessed by PCR and sequencing109
(11). Sequences were compared to those of the blaTEM-1 gene and its promoter region in110
public databases (GenBank accession no. AB194682) (30). In those isolates in which111
the promoter region could not be amplified with these primers, the possibility of linkage112
of blaTEM alleles to IS26-like elements, as suggested previously (1), was assessed with113
primers IS26-F (5′-GCG GTA AAT CGT GGA GTG AT-3′) and TEMi-R (5′-TCT TTT 114
ACT TTC ACC AGC GTT-3′). 115
Genes coding for p-AmpC (CIT, DHA, ACC, EBC, MOX, and FOX) and116
blaOXA-1 were characterized by PCR amplification with specific primers and sequencing117
(2, 24, 26) in all isolates. E. coli isolates with a negative result for p-AmpC β-118
lactamases but that displayed a resistance phenotype consistent with AmpC production119
on the basis of their resistance to AMC and cefoxitin, and inhibition with phenyl120
boronic acid and cloxacillin (cefotetan/cefotetan-cloxacillin E-test [AB Biomerieux,121
Solna, Sweden]), were categorized as c-AmpC.122
Isolates only carrying the blaTEM-1 or blaSHV-1 genes with resistance to ampicillin,123
AMC, and cefazolin but susceptibility to the remaining β-lactam antibiotic families 124
were considered penicillinase hyperproducers. In the case of SHV-1, an increase of125
ceftazidime MIC was also considered compatible with a hyperproduction of this126
enzyme (19).127
Genes coding ESBL enzymes (CTX-M, SHV-type, and TEM-type) were studied128
by PCR and sequencing in all AMC-resistant E. coli isolates with an phenotype129
consistent with ESBL-production on the basis of their resistance to the extended130
spectrum cephalosporins whose activity was recovered in presence of clavulanate (24).131
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Phylogenetic groups and O25b type detection133
The phylogenetic groups of AMC-resistant E. coli isolates were determined by a134
multiplex PCR assay described by Clermont et al. (4). To search for an ST131/B2/O25b135
E. coli clone, the O25b type detection was performed with an allele-specific PCR (5).136
137
Molecular epidemiology138
The genetic relationship between the AMC-resistant E. coli isolates was139
determined by pulsed-field gel electrophoresis (PFGE) after total chromosomal DNA140
digestion with XbaI (24).141
A selected sample of 43 AMC-resistant E. coli isolates, representing the two142
major PFGE clusters (19 isolates each) and 5 IRTs-producing isolates belonging to143
serotype O25b phylogroup B2 isolates, was studied further by multilocus sequence144
typing (MLST), according to the University College Cork (Éire) scheme for E. coli145
(http://mlst.ucc.ie/mlst/dbs/Ecoli; data last accessed July 20, 2011).146
147
Statistical analyses148
Differences in the prevalence of mechanisms of resistance and phylogroups149
between different groups were assessed by Fisher’s exact test. Association was150
determined by calculation of the odds ratio (OR) with 95% confidence intervals (CI).151
The null hypothesis was rejected for values of P < 0.05. Statistical analyses were152





Bacterial isolates and mechanisms of AMC resistance157
A total of 257 clinical AMC-resistant E. coli isolates were collected, 110 of them158
(43%) produced nosocomial-acquired infections, and 147 (57%) putatively community-159
acquired infections; 170 (65.9%) were from urine, 30 (12%) from wound, 19 (7.4%)160
from blood, and 38 (14.7%) from other clinical samples.161
During the study period, the participant hospitals had a prevalence of AMC162
resistance in E. coli (MIC ≥ 32/16 µg/ml) of 9.3% (range: 3.3%–13.5%).  163
The mechanisms of resistance detected were: production of OXA-1 (67 isolates,164
26.1%), hyperproduction of penicinillinase (58, 22.6%; 53 TEM-1 and 5 SHV-1),165
production of p-AmpC (50, 19.5%), hyperproduction of c-AmpC (47, 18.3%), and166
production of IRTs (45, 17.5%). In one AMC-resistant isolate with the ESBL167
phenotype, blaTEM-12 was detected linked to an IS26 element upstream of blaTEM. In two168
isolates, no enzymatic mechanism of resistance to AMC was identified. Two different169
mechanisms of AMC resistance were present in 13 isolates: OXA-1+p-AmpC (7170
isolates, 2.7%) and OXA-1+c-AmpC (6 isolates, 2.3%).171
The IRTs identified in this study were TEM-40 (15, 33.3%), TEM-30 (13,172
28.9%), TEM-33 (5, 11.1%), TEM-32 (2, 4.4%), TEM-34 (2, 4.4%), TEM-35 (1,173
2.2%), TEM-54 (1, 2.2%), TEM-76 (1, 2.2%), TEM-79 (1, 2.2%), and the new TEM-174
185 (4, 8.8%), first described in this study.175
Of the 50 p-AmpC β-lactamases detected in our study, 37 (74%) were CMY-2; 176
11 (22%), DHA-1; 1 (2%), CMY-30; and 1 (2%), CMY-42 (2%).177
There were some relevant geographical differences in the prevalence of the178
AMC resistance mechanisms. For instance, p-AmpC mechanism was more prevalent in179
the isolates from the Sant Pau Hospital, Catalonia (45.7%, P = 0.0001) in comparison180
with isolates from the other hospitals; c-AmpC was also more prevalent in isolates from181
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the Vall d’Hebron Hospital, Catalonia (37.5%, P = 0.022); OXA-1 was more prevalent182
in isolates from the Complejo Hospitalario A Coruña, Galicia (46.5%, P = 0.0019); and183
IRT was more prevalent in isolates from the Gregorio Marañón Hospital, Madrid, (30%,184
P=0.038).185
Previous studies detected the hyperproduction of penicillinases (13, 25, 29),186
mainly TEM-1, and AmpC production (17, 20) as the most common mechanisms of187
resistance to AMC in E. coli. A 2011 study showed that of 50 ampicillin/sulbactam188
resistant E. coli isolates from the United States, 96% produced blaTEM-1, 8%, blaCMY-2,189
and 8%, blaOXA-1 (32).190
Some information about p-AmpC production in AMC-resistant E. coli has been191
published (17, 20, 25, 29); one study from the United States reported that of 69 E. coli192
isolates resistant to AMC, 5.8% produced CIT (13).193
Production of OXA-1 in E. coli has been sporadically described previously (13,194
17, 20, 25). The highest reported OXA-1 prevalence (15.3%) was observed in isolates195
from the United States collected between 1990 and 1994 (29); by the end of last196
century, this figure was 7.6% (25) and 2.6% (20) in two Spanish hospitals.197
The prevalence of IRTs found in this study is among the highest reported in198
AMC-resistant E. coli (13, 20, 25, 29). However, of 255 E. coli isolates resistant to199
AMC studied in France in 1996-1998, 37.7% produced IRTs (17). Recently, in a single200
Spanish hospital (18) 11.8% of AMC-resistant E. coli produced IRTs.201
Overexpression of blaTEM-1 has been associated with promoters PaPb, P4 and202
other (11, 15, 31); but in this study this association was not clearly observed since203
50.9% of our TEM-1 producers had the most commonly found P3 promoter (Table 1).204
However, our findings are consistent with a previous report of a 54.5% prevalence of205
P3/TEM-1 among ampicillin/sulbactam resistant E. coli isolates (32). In our study, the206
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most prevalent strong promoter was PaPb, as previously described (32) (Table 1).207
Among our IRTs, 62.2% had promoters other than P3, most of which were PaPb (Table208
1). Implications of the promoter variations in the AMC resistance requires further209
elucidation. The occurrence of IS26 located at different positions upstream of the blaTEM210
gene has been recently described (1), but the influence of this insertion in the expression211
of the blaTEM is unclear so far.212
A total of 37 isolates (14.4%) produced ESBLs: 28 (75.7%) CTX-M-15, 7213
(18.9%) CTX-M-14, 1 (2.7%) SHV-12, and 1 (2.7%) TEM-12. All but one of them had214
an additional AMC resistance mechanism, mainly OXA-1 (67.6%), p-AmpC (13.5%),215
c-AmpC (13.51%), and IRTs (5.4%). Complex mutant TEM β-lactamases were not 216
detected.217
In relation to the AMC resistance mechanisms, no significant difference were218
found between community and nosocomial isolates, except for blaTEM-1 promoters other219
than P3 which were more frequent in nosocomial AMC-resistant E. coli (P < 0.05).220
Table 2 shows the distribution of MIC50, MIC90, MIC ranges and the percentages221
of isolates with MIC > 32/16 µg/mL according to the molecular mechanisms of222
resistance to AMC. OXA-1 producing isolates had AMC MICs lower than isolates with223
other AMC resistance mechanisms (P < 0.03).224
Resistance to non-β-lactam antibiotics in relation to the mechanism AMC-225
resistance is detailed in Table 3. OXA-1-producing isolates were more resistant to226
ciprofloxacin, cotrimoxazole, and aminoglycosides than IRT, AmpC, or TEM-1227
producers (P < 0.001).228
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Phylogenetic groups and O25b type detection230
Of the 257 AMC-resistant E. coli isolates, 76 (29.6%) belonged to phylogenetic231
group A, 32 (12.4%) to group B1, 104 (40.5%) to group B2, and 45 (17.5%) to group D.232
Phylogroup A was more frequent in OXA-1 producers (36, 53.7%; P < 0.0003);233
phylogroup B2, in IRT producers (24, 53.3%; P = 0.06), p-AmpC producers (21, 42%;234
P = 0.87), and TEM-1 producers carrying promoters other than P3 (16, 61.6%; P <235
0.03); and phylogroup D, in P3/TEM-1 producers (13, 48.1%; P < 0.0001).236
Of the 104 phylogroup B2 isolates, 56 (21.8% of all isolates) were serotype237
O25b, being detected in all seven participant hospitals. Of the O25b/B2 isolates, 22238
(39.3%) were OXA-1 producers, 15 (26.8%) were TEM-1 producers with different239
promoters, 11 (19.6%) were p-AmpC producers, 8 (14.3%) were c-AmpC producers,240




A high degree of genetic diversity was observed according to PFGE, as 235245
different PFGE patterns were obtained from the 257 AMC-resistant E. coli isolates246
analyzed. However, two well-defined clusters were detected: cluster C1 (genetic linkage247
> 90%) consisting of 19 OXA-1-producing isolates of phylogroup A, detected in six of248
the seven participant hospitals; and cluster C2 (genetic linkage > 80%) consisting of 19249
AMC-resistant isolates of phylogoup B2 and serotype O25b, detected in six of the seven250
participant hospitals. Of these 19 C2 isolates, 12 produced OXA-1 and CTX-M-15; 3251
produced OXA-1 only; 3 produced CTX-M-15 and c-AmpC; and one produced CTX-252
M-15 and DHA. Figure 1 shows the PFGE profiles of the 67 OXA-1-producing isolates.253
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By MLST, the PFGE C1 cluster was identified as ST88, and the PFGE C2254
cluster as ST131.255
Dissemination of OXA-1 β-lactamase in AMC-resistant E. coli isolates in Spain256
is due in part to the clonal spread of the epidemic ST131 clone producing CTX-M-15257
and OXA-1, and to the spread of the ST88 phylogroup A clone only producing OXA-1,258
an association first described here. ST88 has been previously described in association259
with c-AmpC production in a French hospital (6). On the Website of the University260
College of Cork (Ireland), 23 ST88 E. coli isolates are registered and were recovered261
from infections of humans and domestic animals (http://mlst.ucc.ie/mlst/dbs/Ecoli, data262
last accessed July 20, 2011)263
In 24 O25b/B2 isolates, including 19 C2 isolates and five IRTs, MLST was264
performed and showed that all of them were ST131. We found that O25b/B2/ST131 E.265
coli isolates not only carried CTX-M-15 and OXA-1 enzymes as previously reported,266
but also TEM-30, TEM-34, TEM-40, and TEM-54 IRT enzymes. To the best of our267




The new IRT TEM-185 has a double amino acid substitution at positions 69272
(M→L) and 165 (W→L) in comparison with TEM-1 (GenBank accession number 273
1446016); these positions are frequently modified in IRT enzymes. TEM-185 is similar274
to TEM-39 except that the latter has an additional substitution at position 276 (N→D) 275
(http://www.lahey.org/studies/temtable.asp, data last accessed August 2, 2011).276
TEM-185 was detected in four E. coli belonging to phylogroup A; they were277
isolated in two geographically distant Spanish hospitals with two isolates each; two of278
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them were closely related (genetic similarity >85% and same P4 promoter), the two279
additional isolates were genetically unrelated and had two different promoters, P4 and280
Pdel. These findings suggest that several clones can spread TEM-185.281
282
Concluding remarks283
Our findings suggest a complex epidemiological background in which E. coli284
acquire AMC resistance by several mechanisms, including clonal (ST131, ST88) and285
non-clonal spread, dissemination of mobile genetic elements carrying different bla286
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Table 1. The frequency of promoter regions and insertions and deletions identified in424








P3 PaPb P4 Pdel
TEM-1 (53) 27 18 2 - 4 1 1
TEM-40 (15) 6 6 3 - - - -
TEM-30 (13) 5 6 1 - 1 - -
TEM-33 (5) 2 3 - - - - -
TEM-185 (4) - - 3 1 - - -
TEM-32 (2) 2 - - - - - -
TEM- 34 (2) 2 - - - - - -
TEM-35 (1) - 1 - - - - -
TEM-76 (1) - 1 - - - -
TEM-79 (1) - 1 - - - - -
All data represent the number of affected isolates, n.426
*The IS26 element was detected upstream of blaTEM, inserted at promoter positions 150427
(n=3) or 46 (n=2) according to the Sutcliffe numbering system (16).428
#The IS911 element was detected upstream of blaTEM-1, inserted at promoter position 46.429
430
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Table 2. Distribution of MIC50, MIC90, MIC range, and percentage of431
amoxicillin/clavulanate resistant Escherichia coli isolates with MIC>32/16 µg/ml in432












OXA-1 (54) 32/16 64/32 16/8-128/64 40.3%
IRT (45) 64/32 128/64 16/8->128/64 93.3%
p-AmpC (43) 64/32 128/64 32/16->128/64 92%
c-AmpC (41) 64/32 128/64 32/16-128/64 83%
P3/TEM-1 (27) 64/32 64/32 16/8->128/64 66.7%
Pdf3/TEM-1* (26) 64/32 >128/64 16/8->128/64 84.6%
OXA-1+AmpC (13) 64/32 64/32 32/16-64/32 53.8%
435





Table 3. Resistance to non-β-lactam antibiotics in relation to the mechanism of 440














TEM-1 (53) 27 (51.8) 7 (13.2) 10 (20.4) 0 30 (56.6)
IRTs (45) 17 (37.8) 4 (8.9) 4 (8.9) 0 24 (53.3)
OXA-1 (67) 57 (85.1) 34 (50.7) 55 (82.1) 12 (17.9) 55 (82.1)
AmpC (97) 51 (52.6) 17 (17.5) 23 (23.7) 1 (1) 44 (45.4)







Figure 1. Dendrogram illustrating the percentage linkage of pulsed-field-gel-447
electrophoresis profiles of 67 OXA-1-producing Escherichia coli isolates448
resistant to amoxicillin-clavulanate.449
450
451
452
